Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study

Schizophrenia Research

Volumn 152, Issue 2-3, 2014, Pages 344-349

  Tinazzi, Michele ^a   Morgante, Francesca ^b   Matinella, Angela ^a   Bovi, Tommaso ^a   Cannas, Antonino ^c   Solla, Paolo ^c   Marrosu, Francesco ^c   Nicoletti, Alessandra ^d   Zappia, Mario ^d   Luca, Antonina ^e   Di Stefano, Angela ^e   Morgante, Letterio ^b   Pacchetti, Claudio ^f   Minafra, Brigida ^f   Sciarretta, Massimo ^f   Dallocchio, Carlo ^g   Rossi, Simone ^h   Ulivelli, Monica ^h   Ceravolo, Roberto ⁱ   Frosini, Daniela ⁱ   Cipriani, Andrea ^a   Barbui, Corrado ^a   more..

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^f C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^g Civil Hospital   (Italy)

^h UNIVERSITY OF SIENA   (Italy)

ⁱ UNIVERSITY OF PISA   (Italy)

Author keywords

123I FP CIT SPECT; Antipsychotic drugs; Dopamine receptor blocking agents; Levodopa; Parkinson's disease; Schizophrenia

Indexed keywords

DOPAMINE TRANSPORTER; IOFLUPANE I 123; LEVODOPA; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; DISEASE COURSE; DRUG RESPONSE; FEMALE; FOLLOW UP; FUNCTIONAL NEUROIMAGING; HUMAN; LONG TERM EXPOSURE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSONISM; PREDICTIVE VALUE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE;

(123)I-FP-CIT SPECT; 123I-FP-CIT SPECT; ANTIPSYCHOTIC DRUGS; APS; DAT; DIP; DOPAMINE RECEPTOR BLOCKING AGENTS; DOPAMINE TRANSPORTER; DRBA; DRUG-INDUCED PARKINSONISM; LEVODOPA; MOTOR SECTION; PARKINSON'S DISEASE; PD; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY OF DOPAMINE TRANSPORTER; UPDRS III=UNIFIED PARKINSON'S DISEASE RATING SCALE;

ADULT; AGE FACTORS; AGED; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84892860946     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.11.028     Document Type: Article

References (25)

1. Benamer T.S., Patterson J., Grosset D.G., Booij J., de Bruin K., van Royen E., Speelman J.D., Horstink M.H., Sips H.J., Dierckx R.A., Versijpt J., Decoo D., van der L.C., Hadley D.M., Doder M., Lees A.J., Costa D.C., Gacinovic S., Oertel W.H., Pogarell O., Hoeffken H., Joseph K., Tatsch K., Schwarz J., Ries V. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov. Disord. 2000, 15:503-510.
2. Bovi T., Antonini A., Ottaviani S., Antonioli A., Cecchini M.P., Di F.V., Bassetto M.A., Zamboni M., Fiaschi A., Moretto G., Sbarbati A., Osculati F., Tinazzi M. The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. J. Neurol. 2010, 257:1882-1889.
3. Burn D.J., Brooks D.J. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology 1993, 43:552-556.
4. Darcourt J., Booij J., Tatsch K., Varrone A., Vander B.T., Kapucu O.L., Nagren K., Nobili F., Walker Z., Van Laere K. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:443-450.
5. Efron B., Tibsirani R. Bootstrap methods of standard errors, confidence intervals, and other measures of statistical accuracy. Stat. Sci. 1986, 1:154-177.
6. Evans J.R., Mason S.L., Williams-Gray C.H., Foltynie T., Brayne C., Robbins T.W., Barker R.A. The natural history of treated Parkinson's disease in an incident, community based cohort. J. Neurol. Neurosurg. Psychiatry 2011, 82:1112-1118.
7. Foubert-Samier A., Helmer C., Perez F., Le Goff M., Auriacombe S., Elbaz A., Dartigues J.F., Tison F. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology 2012, 79:1615-1621.
8. Hassin-Baer S., Sirota P., Korczyn A.D., Treves T.A., Epstein B., Shabtai H., Martin T., Litvinjuk Y., Giladi N. Clinical characteristics of neuroleptic-induced parkinsonism. J. Neural Transm. 2001, 108:1299-1308.
9. Kagi G., Bhatia K.P., Tolosa E. The role of DAT-SPECT in movement disorders. J. Neurol. Neurosurg. Psychiatry 2010, 81:5-12.
10. Kertelge L., Bruggemann N., Schmidt A., Tadic V., Wisse C., Dankert S., Drude L., van d.V., Siebner H., Pawlack H., Pramstaller P.P., Behrens M.I., Ramirez A., Reichel D., Buhmann C., Hagenah J., Klein C., Lohmann K., Kasten M. Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease. Mov. Disord. 2010, 25:2665-2669.
11. Lopez-Sendon J.L., Mena M.A., de Yebenes J.G. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging 2012, 29:105-118.
12. Lorberboym M., Treves T.A., Melamed E., Lampl Y., Hellmann M., Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov. Disord. 2006, 21:510-514.
13. Maurer I., Moller H.J. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell. Biochem. 1997, 174:255-259.
14. Pal G., Goetz C.G. Assessing bradykinesia in parkinsonian disorders. Front. Neurol. 2013, 4:54.
15. Park J., Chung S., An H., Kim J., Seo J., Kim D.H., Yoon S.Y. Haloperidol and clozapine block formation of autophagolysosomes in rat primary neurons. Neuroscience 2012, 209:64-73.
16. Rajput A.H., Rozdilsky B., Hornykiewicz O., Shannak K., Lee T., Seeman P. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch. Neurol. 1982, 39:644-646.
17. Reader T.A., Ase A.R., Huang N., Hebert C., van Gelder N.M. Neuroleptics and dopamine transporters. Neurochem. Res. 1998, 23:73-80.
18. Scherfler C., Schwarz J., Antonini A., Grosset D., Valldeoriola F., Marek K., Oertel W., Tolosa E., Lees A.J., Poewe W. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov. Disord. 2007, 22:1229-1238.
19. Sommer U., Hummel T., Cormann K., Mueller A., Frasnelli J., Kropp J., Reichmann H. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov. Disord. 2004, 19:1196-1202.
20. Susatia F., Fernandez H.H. Drug-induced parkinsonism. Curr. Treat. Options Neurol. 2009, 11:162-169.
21. Tinazzi M., Antonini A., Bovi T., Pasquin I., Steinmayr M., Moretto G., Fiaschi A., Ottaviani S. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J. Neurol. 2009, 256:910-915.
22. Tinazzi M., Cipriani A., Matinella A., Cannas A., Solla P., Nicoletti A., Zappia M., Morgante L., Morgante F., Pacchetti C., Sciarretta M., Dallocchio C., Rossi S., Malentacchi M., Ceravolo R., Frosini D., Sestini S., Bovi T., Barbui C. [(1)(2)(3)I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. Schizophr. Res. 2012, 139:40-45.
23. Tinazzi M., Ottaviani S., Isaias I.U., Pasquin I., Steinmayr M., Vampini C., Pilleri M., Moretto G., Fiaschi A., Smania N., Giorgetti P., Antonini A. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. Mov. Disord. 2008, 23:1825-1829.
24. Valchar M., Hanbauer I. Comparison of [3H]WIN 35,428 binding, a marker for dopamine transporter, in embryonic mesencephalic neuronal cultures with striatal membranes of adult rats. J. Neurochem. 1993, 60:469-476.
25. Velseboer D.C., Broeders M., Post B., van Geloven N., Speelman J.D., Schmand B., de Haan R.J., de Bie R.M. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology 2013, 80:627-633.